StockWatch
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultJul 14, 2026, 06:06 AM

Evotec Lowers FY26 Revenue Outlook to €570-610M; H1 Rev €300.1M

AI Summary

Evotec SE announced preliminary unaudited financial results for H1 2026, reporting Group revenues of approximately €300.1 million and adjusted Group EBITDA of -€42.7 million. The company significantly updated its full-year 2026 outlook, now expecting Group revenues of €570-610 million and adjusted Group EBITDA of -€70 to -105 million, down from previous guidance. This revision is primarily attributed to timing delays in existing and new strategic partnerships, with some revenues shifting to 2027. Despite the lowered outlook, Evotec noted positive base business momentum, including a 28% year-on-year increase in D&PD net sales.

Key Highlights

  • Preliminary H1 2026 Group revenues of approximately €300.1 million.
  • Preliminary H1 2026 adjusted Group EBITDA of approximately -€42.7 million.
  • Updated FY 2026 Group revenue guidance: €570-610 million (previously €700-780 million).
  • Updated FY 2026 adjusted Group EBITDA guidance: -€70 to -105 million (previously €0-40 million).
  • Approximately 40% of revenue difference shifted to 2027 due to revised phasing and milestone schedules.
  • Approximately 45% of revenue difference due to delays in new strategic partnerships.
  • D&PD net sales increased by approximately 28% year-on-year in H1 2026.
  • Liquidity as of June 30, 2026, expected to be approximately €465.6 million.